Zimmer Biomet Holdings, Inc. (ZBH) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Zimmer Biomet financial statements at a glance

Zimmer Biomet reported revenue of $8.23 billion for fiscal year 2025 (ended December 31, 2025), up 7.2% from fiscal year 2024. Net income was $705.20 million, a net margin of 8.6%.

At the end of fiscal year 2025 it had total assets of $23.09 billion, total liabilities of $10.39 billion and shareholders' equity of $12.70 billion, with total debt of $7.52 billion.

Its operations brought in $1.70 billion of cash.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

ZBH logo

Zimmer Biomet Holdings, Inc.

ZBHUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Revenue
8.23B
Prev Year: 7.68B
YoY: +7.2%
Total Revenue
-
Cost of Revenue
2.49B
Prev Year: 2.19B
YoY: +13.8%
Gross Profit
5.74B
Prev Year: 5.49B
YoY: +4.6%
SG&A Expenses
3.23B
Prev Year: 2.90B
YoY: +11.6%
Operating Expense
-
R&D Expense
458.50M
Prev Year: 437.40M
YoY: +4.8%
Depreciation/Amortization
665.90M
Prev Year: 591.90M
YoY: +12.5%
Net Non Operating Interest Income Expense
-
Operating Expenses
7.13B
Prev Year: 6.39B
YoY: +11.6%
Other Income Expense
-
Operating Income
1.10B
Prev Year: 1.29B
YoY: -14.6%
Pre-tax Income
-
Interest Inc.(Exp.),Net-Non-Op., Total
-292.80M
Prev Year: -218.00M
YoY: -34.3%
Other, Net
25.50M
Prev Year: -31.10M
YoY: +182.0%
Net Income Common Stockholders
-
Net Income Before Taxes
830.80M
Prev Year: 1.04B
YoY: -19.9%
Diluted NI Available to Com Stockholders
-
Provision for Income Taxes
125.70M
Prev Year: 131.40M
YoY: -4.3%
Basic EPS
-
Net Income After Taxes
705.10M
Prev Year: 905.20M
YoY: -22.1%
Diluted EPS
-
Net Income Before Extra. Items
705.20M
Prev Year: 903.70M
YoY: -22.0%
Weighted Average Shares (basic)
-
Net Income
705.20M
Prev Year: 903.70M
YoY: -22.0%
Total Extraordinary Items
-
Weighted Average Shares (diluted)
-
Total Adjustments to Net Income
-100.0K
Prev Year: 100.0K
YoY: -200.0%
Total Operating Income as Reported
-
Income Available to Com Excl ExtraOrd
705.10M
Prev Year: 903.80M
YoY: -22.0%
Total Expenses
-
Income Available to Com Incl ExtraOrd
705.10M
Prev Year: 903.80M
YoY: -22.0%
Net Income from Continuing and Discontinued Operation
-
Diluted Net Income
705.10M
Prev Year: 903.80M
YoY: -22.0%
Normalized Income
-
Diluted Weighted Average Shares
198.70M
Prev Year: 203.90M
YoY: -2.6%
Interest Expense
-
Diluted EPS Excluding ExtraOrd Items
3.549
Prev Year: 4.433
YoY: -19.9%
Net Interest Income
-
DPS - Common Stock Primary Issue
0.96
Prev Year: 0.96
YoY: 0.0%
EBIT
-
Diluted Normalized EPS
4.748
Prev Year: 5.602
YoY: -15.2%
EBITDA
-
Unusual Expense (Income)
280.80M
Prev Year: 273.10M
YoY: +2.8%
Reconciled Cost of Revenue
-
Minority Interest
100.0K
Prev Year: -1.50M
YoY: +106.7%
Reconciled Depreciation
-
Values in USD

Zimmer Biomet key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$8.2B$7.7B$7.4B$6.9B$6.8B
Gross profit$5.7B$5.5B$5.3B$4.9B$4.9B
Operating income$1.1B$1.3B$1.3B$696.3M$1.0B
Net income$705.2M$903.7M$1.0B$231.4M$401.6M
Diluted EPS––––$1.91
Total assets$23.1B$21.4B$21.5B$21.1B$23.5B
Total liabilities$10.4B$8.9B$9.0B$9.0B$10.8B
Shareholders' equity$12.7B$12.5B$12.5B$12.0B$12.7B
Cash––––$378.1M
Total debt$7.5B$6.2B$5.8B$5.7B$7.1B
Operating cash flow$1.7B$1.5B$1.6B$1.3B$1.5B
Capital spending––––$152.0M
Free cash flow––––$1.3B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2020.

Questions and answers

What was Zimmer Biomet's revenue in fiscal year 2025?

$8.23 billion, up 7.2% from $7.68 billion in fiscal year 2024.

How much profit does Zimmer Biomet make?

Zimmer Biomet reported net income of $705.20 million for fiscal year 2025 (8.6% of revenue); operating income was $1.10 billion.

How much cash and debt does Zimmer Biomet have?

At the end of fiscal year 2025: total debt of $7.52 billion.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube